PD-L1 expression by tumor or tumor-infiltrating immune cells is a general phenomenon in EBV and MSI subtypes, supporting the detection of PD-L1 in these patient populations and the assessment of EBV and MSI status as a key factor in immunotherapy for gastric cancer [31, 32]. Here, CD274 is linked to neoplasm.